Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-hodgkin's lymphoma

Pharmacotherapy

Volumn 19, Issue 1 I, 1999, Pages 101-107

  Higa, Gerald M ^a,c   Sarkar, Mohamadi A ^a   DeVore, Russell F ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PHARMACODYNAMICS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SMALL CELL; DRUG EVALUATION; DRUG MONITORING; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED;

EID: 0032948224     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.1.101.30508     Document Type: Article

References (29)

1. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
2. Cavelli F, Sonntag RW, Jungi F, Senn HJ, Brunner KW. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 1978;62:473-5.
3. Fisher RI, DeVita VT, Hubbard SM, et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequence of ProMACE and MOPP chemotherapy. Ann Intern Med 1983;98:304-9.
4. Williams SD, Birch R, Irwin L, et al. Disseminated germ cell tumors: chemotherapy with cisplatin plus bleomycin plus either vinblastine or etoposide. N Engl J Med 1987;316: 1435-40.
5. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-75.
6. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 1989;28:6157-60.
7. Slevin ML, Clark PI, Joel SP. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-40.
8. Drewinko B, Barlogie B. Survival and cell-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat Rep 1976;60:1295-1306.
9. Creaven PJ, Allen LM. EPEG, a new antineoplastic epipodophyllotoxin. Clin Pharmacol Ther 1975;18:221-6.
10. Lawrie S, Dodson M, Arnold A, Whitehouse JMA. Pharmacokinetics and bioavailability of VP-16-213 in man. Cancer Chemother Pharmacol 1982;7:236-7.
11. Stewart DJ, Nundy D, Maroun JA, Teireault L, Prior J. Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 1985;69:269-73.
12. Sinkule JA, Evans W. High performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. J Pharm Sci 1981;73:168-74.
13. Duncan GF, Farmen RH, Movahhem HS, Pittman KA. High-performance liquid chromatographic method for the determination of etoposide in plasma using electrochemical detection. J Chromatogr 1986;380:357-65.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;6:31-41.
15. Scientific Consulting Incorporated Software. PCNONLIN V 3.01 reference manual. Cary, NC: Scientific Consulting Incorporated Software, 1989.
16. Conley BA, Forrest A, Egorin MJ, et al. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res 1989;49:3436-40.
17. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to improved therapeutic index in head and neck cancer. Br J Cancer 1989;59:287-90.
18. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 1991;9:1480-6.
19. Joel S, O'Byrne K, Penson R, et al. A randomized, concentration-controlled comparison of standard (5 day) versus prolonged (15 day) infusions of etoposide phosphate in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1997;16:451a.
20. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993;11:374-7.
21. Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier oncology group study. Semin Oncol 1990;17(suppl 2):32-5.
22. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 1987;47:1952-6.
23. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990;8:1613-17.
24. Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide - a phase I trial. J Clin Oncol 1989;7:396-401.
25. D'Incalci M, Farina P, Sessa C, et al. Pharmacokinetics of VP 16-213 given by different administration methods. Cancer Chemother Pharmacol 1982;7:141-5.
26. Arbuck SG, Douglass HO, Crom WR, Goodwin P. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 1986;11:1690-5.
27. Sinkule J, Hutson P, Hayes FA, Etcubanas E, Evans W. Pharmacokinetics of etoposide (VP-16) in children and adolescents with refractory solid tumours. Cancer Res 1984;44:3109-13.
28. Wolff SN, Grosh WW, Prater K, Hande KR. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 1987;19: 246-9.
29. Ratain MJ, Schilsky RL, Conley BA, et al. Pharmacodynamics in cancer therapy. J Clin Oncol 1990;8:1739-53.